The multifactorial origin and neurochemistry of Alzheimer’sdisease (AD) call for the development of multitarget treatment strategies.We report a first-in-class triple acting compound that targets serotonintype 6 and 3 receptors (5-HT-Rs) and monoamine oxidase type B (MAO-B)as an approach for treating AD. The gene discussed is MAOB; the disease is Alzheimer disease.